Adaptive Biotechnologies delivered a strong performance in Q4 2025, with revenue increasing by 51% year-over-year to $71.7 million. The MRD business achieved profitability and contributed significantly to revenue growth, while the company also made strides in its Immune Medicine platform and secured new data partnerships.

Adaptive Biotechnologies delivered an outstanding second quarter, achieving profitability in its MRD business with accelerating top- and bottom-line growth. The company reported total revenue of $58.9 million, a 36% increase year-over-year, driven primarily by a 42% growth in the MRD business. Net loss significantly decreased to $25.6 million from $46.2 million in the prior year.

Adaptive Biotechnologies reported a strong start to 2025 with total revenue of $52.4 million, a 25% increase from the prior year. The MRD business, contributing 83% of total revenue, grew 34% year-over-year, driven by a 36% increase in clonoSEQ test volume. The company also significantly reduced its net loss and adjusted EBITDA loss compared to the previous year.

Adaptive Biotechnologies reported a revenue of $47.5 million for the fourth quarter of 2024, a 4% increase from the prior year. The company's net loss significantly decreased to $33.7 million from $69.5 million in the same period last year, and adjusted EBITDA loss improved to $16.4 million from $24.7 million.

Adaptive Biotechnologies reported a 22% increase in revenue compared to the third quarter of the prior year, with MRD revenue growing by 52%. The company's focus on execution and disciplined capital allocation drove MRD growth with a clear path to profitability, while they continue to advance their targeted Immune Medicine programs.

Adaptive Biotechnologies reported a revenue of $43.2 million for the second quarter of 2024. The MRD business grew by 36% compared to the second quarter of 2023. The company also delivered significant reductions in operating spend and cash burn versus prior year.

Adaptive Biotechnologies reported revenue of $41.9 million for Q1 2024, an 11% increase year-over-year. The MRD business grew by 52%, contributing 78% of the total revenue. The company's net loss was $47.5 million, an improvement from the $57.7 million loss in the same period last year. They are focusing on separate segment reporting and disciplined capital allocation for MRD and Immune Medicine.

Adaptive Biotechnologies reported a revenue of $45.8 million for the fourth quarter of 2023, a 17% decrease compared to the prior year. The MRD business grew by 9%, while the Immune Medicine business decreased by 45%. The net loss for the quarter was $69.5 million, compared to $40.2 million for the same period in 2022.

Adaptive Biotechnologies reported a 21% decrease in revenue compared to the third quarter of the prior year, driven by reductions in GNE amortization and MRD/IM pharma services. The company is undergoing a strategic review to maximize the value of its MRD and Immune Medicine businesses. clonoSEQ test volume grew 56% year-over-year.

Adaptive Biotechnologies reported a revenue of $48.9 million for the second quarter of 2023, representing a 12% increase compared to the same period last year. The company continues to drive operational efficiencies, as reflected by a 5% decrease in operating expenses, excluding the cost of revenue.

Adaptive Biotechnologies reported a 3% decrease in revenue for the first quarter of 2023, totaling $37.6 million, while clonoSEQ test volume increased by 57%. The company reiterated its full year 2023 revenue guidance to be in the range of $205 million to $215 million.

Adaptive Biotechnologies reported a revenue of $55.2 million for Q4 2022, a 46% increase compared to the previous year. The company's net loss was $40.2 million, and adjusted EBITDA was a loss of $19.6 million. They ended the year with $498.2 million in cash, cash equivalents and marketable securities.

Adaptive Biotechnologies reported a 21% increase in revenue compared to the third quarter of the prior year. The company is focused on driving growth and innovation with a clear path to profitability.

Adaptive Biotechnologies reported a strong second quarter with a 13% increase in revenue compared to the previous year, driven by growth in both the MRD and Immune Medicine businesses. The company is focused on expanding clonoSEQ adoption and prioritizing pharma partnering and drug discovery opportunities.

Adaptive Biotechnologies reported a slight increase in revenue for Q1 2022, with a strategic reorganization focusing on MRD and Immune Medicine. Total revenue reached $38.6 million, a 0.5% increase compared to Q1 2021. The company's net loss increased to $62.8 million, and operating expenses rose by 28%.

Adaptive Biotechnologies reported a strong finish to the year with a 26% increase in revenue compared to the fourth quarter of the prior year. The growth was driven by both sequencing and development revenue categories. The company recognized $10.0 million in MRD regulatory milestones.

Adaptive Biotechnologies reported a revenue of $39.5 million for Q3 2021, a 50% increase compared to Q3 2020. The company's net loss was $56.0 million, compared to $36.7 million for the same period in 2020.

Adaptive Biotechnologies reported a strong second quarter with significant revenue growth, driven by sequencing and development revenue. The company is also making progress in its immune medicine platform, with emerging data expected to monetize for multiple opportunities.

Adaptive Biotechnologies reported a strong start to the year with revenue increasing 84% year over year. The company's clonoSEQ clinical sequencing volume grew 35% versus the prior year. They also recognized $7.0 million in MRD regulatory milestones.

Adaptive Biotechnologies reported a 25% increase in revenue for the fourth quarter of 2020, driven by a 69% increase in development revenue. The company launched T-Detect COVID and extended its collaboration with Labcorp.

Adaptive Biotechnologies reported a revenue of $26.3 million for Q3 2020, a 1% increase compared to Q3 2019. The company's net loss was $36.7 million, and operating expenses totaled $63.3 million.

Adaptive Biotechnologies reported a slight decrease in revenue compared to the same quarter last year. The company's net loss increased significantly due to higher operating expenses. They are not providing 2020 financial guidance due to COVID-19 uncertainties.

Adaptive Biotechnologies reported a 65% increase in revenue compared to the first quarter of the prior year, with revenue reaching $20.9 million. The company's net loss was $31.4 million for the quarter.

Adaptive Biotechnologies reported strong topline growth in commercial products and critical progress in advancing clinical product pipeline for Q4 2019. Total revenue reached $24.2 million, a 41% increase year-over-year. The company is focused on building commercial infrastructure and expanding R&D resources for immunoSEQ Dx and the Genentech alliance in 2020.